Funder
Pfizer
Novartis
Bristol-Myers Squibb
Eisai
Ipsen
Merck
Genentech
Roche
GlaxoSmithKline
Bayer
Exelixis
Instituto de Salud Carlos III
AstraZeneca
Alexion
Bristol Myers-Squibb
Sons LLC
Cerulean
Foundation Medicine Inc
Tracon
Roche Products Limited
F. Hoffmann-La Roche
Lilly
Peloton
Prometheus Labs
Corvus
Calithera
Analysis Group
Sanofi
Takeda
pharmaceutical companies
Reference21 articles.
1. Check point inhibitors a new era in renal cell carcinoma treatment;Alsharedi;Med Oncol,2018
2. Systemic therapy for metastatic renal-cell carcinoma;Choueiri;N Engl J Med,2017
3. FDA approval summary: nivolumab in advanced renal cell carcinoma after anti-angiogenic therapy and exploratory predictive biomarker analysis;Xu;Oncologist,2017
4. European Medicines Agency. Positive Opinion on the Change to the Marketing Authorisation for Opdivo (nivolumab) and Yervoy (ipilimumab). 2018. Available at: https://www.ema.europa.eu/en/documents/smop/questions-answers-positive-opinion-change-marketing-authorisation-opdivo-nivolumab-yervoy-ipilimumab_en.pdf. Accessed: January 30, 2019.
5. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019